| 16.32 -0.17 (-1.03%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.75 | 1-year : | 24.24 |
| Resists | First : | 17.77 | Second : | 20.75 |
| Pivot price | 16.25 |
|||
| Supports | First : | 14.95 | Second : | 13.21 |
| MAs | MA(5) : | 16.13 |
MA(20) : | 15.73 |
| MA(100) : | 14.2 |
MA(250) : | 15.52 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 55 |
D(3) : | 57.5 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 21.01 | Low : | 11.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SLP ] has closed below upper band by 47.7%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.84 - 16.93 | 16.93 - 17 |
| Low: | 15.93 - 16.02 | 16.02 - 16.09 |
| Close: | 16.19 - 16.33 | 16.33 - 16.44 |
Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.
Thu, 11 Jun 2026
Do options traders know something about Simulations Plus stock we don't? - MSN
Wed, 10 Jun 2026
Securities Investigation Into Simulations Plus, Inc. (SLP) - GlobeNewswire
Thu, 04 Jun 2026
Simulations Plus (SLP) CRO auto-sells 1,000 shares under Rule 10b5-1 plan - Stock Titan
Thu, 04 Jun 2026
Johnson Fistel Investigates Simulations Plus, Inc. (SLP) - GlobeNewswire
Tue, 02 Jun 2026
Simulations Plus (SLP) major holders sell 15,000 shares under 10b5-1 plan - Stock Titan
Fri, 29 May 2026
Is It Too Late To Consider Buying Simulations Plus, Inc. (NASDAQ:SLP)? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 20 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 82.9 (%) |
| Shares Short | 1,390 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | -3.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.61 |
| Profit Margin | -78 % |
| Operating Margin | 23.1 % |
| Return on Assets (ttm) | 3.8 % |
| Return on Equity (ttm) | -38.9 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 2.46 |
| Sales Per Share | 3.98 |
| EBITDA (p.s.) | 0.69 |
| Qtrly Earnings Growth | 46.7 % |
| Operating Cash Flow | 24 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | -5.24 |
| PEG Ratio | 9.8 |
| Price to Book value | 2.46 |
| Price to Sales | 4.09 |
| Price to Cash Flow | 13.52 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|